A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
A Phase 1, Multicenter, Single-Arm Study Evaluating Pharmacokinetic, Pharmacodynamic, Safety, and Clinical Efficacy of Orally Administered Ivosidenib in Chinese Subjects With Relapsed or Refractory Acute Myeloid Leukemia With an IDH1 Mutation
Sponsor: CStone Pharmaceuticals
This PHASE1 trial investigates Relapsed or Refractory Acute Myeloid Leukemia and is currently completed. CStone Pharmaceuticals leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Nov 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CStone Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .